Theresa Lavallee PhD

Theresa LaVallee, PhD, joined the Parker Institute for Cancer Immunotherapy in 2017 as head of translational medicine and regulatory affairs. She has more than 25 years of research and industry experience, with broad knowledge of drug discovery and development.

Previously, Dr. LaVallee served as Senior Vice President of Regulatory and Precision Medicine at Celldex Therapeutics and Senior Vice President of Translational Medicine and Product Development at Kolltan Pharmaceuticals. Prior to those roles, she was Senior Director Translational Medicine at MedImmune and EntreMed. In these positions, she advanced drugs in oncology, immunology and inflammation from discovery through late stage development.

Dr. LaVallee has a depth of expertise in translational medicine to enable science-driven development decisions and to implement effective use of biomarker assays in clinical studies. She is author or co-author of more than 50 publications and abstracts with a focus on translational medicine approaches in clinical development.

She received her doctoral degree in microbiology and molecular genetics from the University of California, Los Angeles and her bachelor’s degree in biochemistry and molecular biology from the University of California, Santa Barbara. Dr. LaVallee completed her postdoctoral research at the American Red Cross Holland Laboratory.